Kleinostheim, Germany, 21st October 2010 – curasan AG, listed in the General Standard of the German Stock Exchange (ISIN: DE 000 549 453 8) has received European approval for its new granular bone regeneration material Ceracell^®.

Hans Dieter Rössler, CEO of curasan AG, considers the CE-certification of Ceracell^® to be another milestone in the implementation of the product offensive launched at the beginning of the year: “We are implementing our strategy of offering innovative biomaterials, customized to the needs of the users, both consistently and persistently. The launch of Ceracell® in the dental market is planned to coincide with the world’s largest international dental exhibition in Cologne (IDS) at the end of March next year, and it will be launched approxi-mately three months later in the orthopaedic market.”

Ceracell^® is a synthetic, completely absorbable and bioactive bone regeneration material. Although the porosity compared to Cerasorb^® has been increased considerably yet again, the material has greater mechanical stability. Thanks to the spongy structure designed after human bones and an optimised formulation an increased number of bone-forming cells dock on Ceracell®, which leads to accelerated and qualitatively better bone regeneration. Ceracell^® is especially suitable when the body’s own healing potency needs to be reinforced by sub-stances for bone growth such as PRP, BMP, bone marrow or stem cells.